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Summary
A number of bills have been introduced in the 106th Congress to establish
prescription drug coverage for the Medicare population. On June 28, 2000, the House
passed the Medicare Rx 2000 Act (H.R.4680, Thomas, et al.). The bill relies on
private plans including Medicare+Choice plans to provide drug coverage; federal
subsidies would be provided to encourage participation.  There would be a maximum
limit on beneficiary out-of-pocket costs (“stop-loss” coverage);  and assistance would
be provided to low-income seniors. The drug benefit and the Medicare+Choice
program would be administered by a new Medicare  Benefits Administration. The
Congressional Budget Office (CBO) cost estimate for the new drug program is  $37
billion over the FY2001-FY2005 period and $147 billion over the FY2001-FY2010
period.
There are several other proposals which have received considerable attention to
date.  These are the President’s plan (S. 2342), the Daschle bill (S. 2541),  Breaux-
Frist 2000 (S. 2807), the Graham/Bryan/Robb bill (S.2758) and the Roth bills (S.3016
and S. 3017).  On June 24, 2000, the President announced several modifications to
his drug plan including starting the program 1 year earlier and placing a limit on
beneficiary out-of-pocket costs. The Congressional Budget Office (CBO) cost
estimate of the revised proposal is $98.4 billion over the FY2001-FY2005 period and
$337.7 billion over the FY2001-FY2010 period.
There are a number of common themes in many of the major prescription drug
bills pending before the Congress.  Most would make coverage available to all
Medicare beneficiaries on a voluntary basis (though one approach would limit
eligibility to those with low-incomes or high drug costs)  They would all have a limit
on the amount of federal spending for the new benefit.  Further, they would all
provide assistance for the low-income. There are major differences among the bills in
how the benefits would be structured.  
It is the degree of reliance placed on the public versus the private sector that
characterizes one of the key areas of difference among the various proposals. All of
the bills would place some measure of responsibility on the private sector for
administration of a drug plan.  Some bills would have the government assume all (or
most) of the risk for providing the benefit while others would transfer more of the risk
to the private entity. Another key difference among the plans is the scope of benefits
to be provided.  Under some bills a specified level of benefits would be available
nationwide.  Under other bills, a minimum benefit level would be established. The bills
also designate different agencies to administer the new benefit at the federal level.
This report provides a side-by-side comparison of the key components of the
major plans currently pending before the Congress.  It is a companion report to CRS
Report RL30584, Medicare: Selected Prescription Drug Proposals; that report
provides more information on these major bills.  Both reports will be updated to
reflect any legislative action.
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Medicare: Side-by-Side Comparison of 
Selected Prescription Drug Bills
The following pages provide a side-by-side comparison of the following bills: 1)
the Medicare Rx 2000 Act (H.R. 4680, Thomas, et al.) as passed by the House on
June 28, 2000; 2) the Administration bill, the Medicare Modernization Act of 2000
(S. 2342, Moynihan), together with the revisions to the plan announced by the
President on June 24, 2000; 3) the Medicare Prescription Drug and Modernization
Act of 2000 (S. 2807, the “Breaux-Frist 2000” bill);  4) the Medicare Expansion for
Needed Drugs (MEND) Act of 2000 (S. 2541, Daschle et al.) announced at the White
House in May 2000; 5) the Medicare Outpatient Drug Act of 2000 (S. 2758, the
“MOD bill” or the “Graham/Bryan/Robb” bill);  and 6) the Medicare Temporary Drug
Assistance Act (S. 3016 and S. 3017).  For further information on these bills, see CRS
Report RL30584, Medicare: Selected Prescription Drug Proposals; that report
provides more information on these major bills.
On June 27, 2000, Congressman Gephardt, together with 111 cosponsors,
introduced H.R. 4770, the Medicare Guaranteed and Defined Rx Benefit and Health
Provider Relief Act of 2000.  On June 28, 2000, during consideration of H.R. 4680,
a point of order was sustained against a motion by Congressman Stark to recommit
the bill to the Committee on Ways and Means with instructions to report it back with
an amendment in the nature of a substitute inserting the provisions of H.R.4770.  The
drug provisions of the Gephardt bill are similar to the provisions of S. 2541, the
Daschle bill (which is included in this side-by-side). The following are the major
differences between the Gephardt bill and the Daschle bill.  The Gephardt bill would:
1) provide coverage for prescription “medicines” not “drugs”; 2) begin in 2003 rather
than 2002; 3) establish the following benefit limits: $2,000 for 2003 and 2004, $3,000
for 2005 and 2006; $4,000 for 2007 and 2008, and $5,000 for 2009 (with the
beneficiary still liable for 50% of these costs); 4) increase these limits in future years
by the percentage increase in the in per capita expenditures for covered medicines; 5)
establish a catastrophic benefit with an out-of-pocket limit not greater than $4,000 (in
2003) and provide funding for the benefit from projected budget surpluses; 6) permit
late enrollment in the program, subject to late enrollment penalties, with the amount
of such penalties based on the associated costs to the program; 7) specify that the
monthly premium would be $25 in 2003 and that the calculation of the premium for
future years would exclude the costs associated with the catastrophic benefit; 8)
specify that the Secretary would divide the country into an “appropriate number” of
service areas and that the entities administering the program in these areas would be
labeled “private benefit administrators”; 9) establish additional criteria, including past
performance, for competitive selection of private benefit administrators; 10) specify
that contracts with participating pharmacies would allow reasonable dispensing and
consulting fees for pharmacists; 11) require the benefit administrator to use a
pharmacy and therapeutics committee in the development and management of its
formulary; and 12) require the benefit administrator to have in place a medication
CRS-2
therapy management program. The Gephardt bill also includes other amendments to
the Medicare program including provisions relating to the appeals process,
Medicare+Choice program, and payments to providers.
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General Approach















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




A new optional benefit
would be established  under
a new Part D. The bill relies
on private plans to provide
coverage and to bear the
financial risk for drug costs;
federal subsidies would be
provided to encourage
participation.  Coverage




could purchase either a
standard plan or an
actuarially equivalent plan.
A new Medicare Benefits
Administration would be
established within HHS to
administer the benefit.
A new optional drug benefit
would be established  under
a new Part D.  (The bill also
includes other Medicare
provisions). The federal
government would bear the
financial risk of coverage. 
The benefit would be
administered by entities
under contract with the
Department of Health and
Human Services (HHS). Any
entity capable of
administering the benefit
could compete for the
contract.  JUNE 24, 2000
REVISION:  the
Administration announced a
revision of the bill.  Under
the revision, the benefit
would begin January 2002
and would include a $4,000
limit on out-of-pocket
spending.
The Commissioner of the
newly established
Competitive Medicare
Agency (CMA) would be
required to establish a
Prescription Drug and
Supplemental Benefit
Program under title XXII of
the Social Security Act. 
Eligible beneficiaries would
voluntarily enroll and receive
access to covered outpatient
drugs and, in certain cases,
other supplemental benefits
through enrollment in either
a Medicare Prescription Plus
plan offered by a private
entity or a M+C plan. These
private plans would be
responsible for assuming the
risk of drug costs. All
persons would receive a
minimum of a 25% discount
on that portion of their
premium related to qualified
prescription drug coverage.
A new optional drug benefit
would be established under a
new Part D.  The federal
government would bear the
financial risk of coverage.  
The benefit would be
administered by private
entities under contract with
HHS.
A new optional drug benefit
would be established under a
new Part D. The benefit
would be administered by
eligible entities under
contract with HHS. The
federal government would
bear most of the financial
risk of coverage.  Higher
income enrollees would
receive a lower contribution
from the federal government
toward the cot of their Part D
premiums. 
The bills would establish a
new temporary Outpatient
Prescription Drug Assistance
Program under a new Title
XXII of the Social Security
Act.  Funds would be
provided  to states
(individually or as part of a




programs could also provide
assistance to Medicare
beneficiaries with high drug
costs. A state’s Title XXII
program would be separate
from its Medicaid program. 
The bills would establish a
default program,
administered by HCFA, for
persons residing in states
which did not establish a
program. The Title XXII
program would be repealed if
a comprehensive Medicare
reform plan, that included
coverage for outpatient
prescription drugs,  was
enacted prior to the sunset
date.  (Both bills are
identical except for the
definition of low-income, the
amounts allocated to the
state, and the sunset dates.)
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Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




January 1, 2003. January 1, 2003. JUNE 24,
2000 REVISION: would
move date to January 2002;
payments would be made to
M+C plans in 2001 for drug
benefits.
January 1, 2003. January 1, 2002. January 1, 2003 October 1, 2000. Program
would sunset December 31,
2003 under S. 3016 and
September 30, 2004, under
S. 3017.
Covered Populations















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




All Part B enrollees who
elected to enroll. A one-time
opportunity would be
provided for Part A-only
beneficiaries.
All Medicare-eligible
individuals who elected to
enroll.
Beneficiaries enrolled in
both Parts A and B who
elected to enroll.
All Medicare-eligible
individuals who elected to
enroll.
All Medicare-eligible
persons who elected to
enroll. 
Eligible persons would be
low-income Medicare
beneficiaries, and, at state
option, beneficiaries with
high drug costs. Low- income
persons would be those with
family income below a state-
established level. This level
could not exceed 150% of
poverty under S. 3016 (175%
under S. 3017).  A higher
level could be established if
a state had an existing drug
assistance program providing
coverage for persons with
incomes up to or exceeding
150% of poverty under S.
3016 (175% under S. 3017).  
Persons eligible for
assistance with high drug
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Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




costs would be those whose
family income exceeded the
level that would qualify them
as low-income and whose
out-of-pocket expenditures
for drugs exceeded the state-




level for the default program
would be 150% of poverty.
Subject to the availability of
funds, the default program
would also cover persons
whose drug costs exceeded a
level specified by HCFA.
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Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




A 6-month enrollment period
would be established at the
beginning of the program; an 
initial 7-month period would
be provided for future
beneficiaries. An annual
election period, similar to
that for M+C plans, would
allow for  changes in
enrollment. Late enrollment
penalties could apply for
persons who did not
maintain continuous drug
coverage.
An open enrollment period
would be established for first
year program was in effect.
A one-time opportunity




There would be a one-time
enrollment opportunity.  A 6-
month enrollment period
would be established at the
beginning of the program; an 
initial 7-month period would
be provided for future
beneficiaries. A special
period would be established
for person involuntarily
losing other coverage. An
annual election period,
similar to that for M+C
plans, would allow for 
changes in enrollment.
An open enrollment period
would be established for first
year program was in effect.
A one-time opportunity





would be similar to that for
Part B.  Individuals initial
enrollment opportunity
would generally occur when
an individual first became
eligible for Medicare.  The
Secretary would establish an
initial open enrollment
period for current enrollees. 
Late enrollment penalties,
similar to those applicable
under Part B, would apply
for persons who did not
enroll during their initial
enrollment period.  An
annual election period,
similar to that for M+C




programs.  HCFA would be
required to establish
procedures for determining



















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)





be either standard coverage
or actuarially equivalent
coverage.  Plans could offer
more generous coverage. 
The Administrator would
administer the program in a
manner such that all
individuals have access to at
least two plans.  If necessary,
Administrator could provide
financial incentives to secure
such access.
A specified benefit would be
available to all enrollees
nationwide.
“Qualified coverage” would
be either standard coverage
or actuarially equivalent
coverage.  Plans could offer
more generous drug
coverage; they could also
offer supplemental non-drug
benefits. If an entity offered
more generous coverage, it
would also be required to
offer a Medicare Prescription
Plus plan in the area meeting
minimum coverage criteria
only.  The Commissioner
would develop procedures
for the provision of standard
prescription drug coverage to
each beneficiary residing in




A specified benefit would be
available to all enrollees
nationwide.
A specified benefit would be
available to all enrollees
nationwide.
Drug assistance provided
under an approved state plan
would be: 1) coverage that
was equivalent to that
provided in a benchmark
benefit package; 2) coverage
that had an aggregate
actuarial value equivalent to
that of a benchmark package,
3) coverage that was
provided under an existing
state-based program, or 4)
another coverage package
approved by the Secretary. A
state could only choose one
of these options. If a state
chose to provide coverage
equivalent to coverage in a
benchmark package, only one



















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




Standard coverage in 2003:
After  $250 deductible, the
plan would pay 50% of costs
up to the next $2100 (i.e.,
$1,050 paid by plan, $1,050
paid by beneficiary).  The
plan would pay no costs for
spending between $2,350
and $7,050.  The plan would
pay 100% of costs when out-
of-pocket costs reached
$6,000 ($7,050 in total
spending).  Dollar amounts
would be increased annually
by annual percent increase in
per capita expenditures for
covered drugs.
Program would pay 50% of
applicable limit: In 2003 and
2004, the program would pay
up to $1,000 per person per
year (out of the first $2,000
in total spending). In 2005
and 2006, it would pay up to
$1,500 (out of the first
$3,000 in total spending). In
2007 and 2008, it would pay
up to $2,000 (out of the first
$4,000 in total spending). In
2009, it would pay up to
$2,500 (out of the first
$5,000 in total spending).
Beginning in 2010, limit
would be increased by the
increase in the consumer
price index (CPI). The bill
would include $35 billion for
catastrophic coverage for
2006-2010 (specifics not
provided).  JUNE 24, 2000
REVISION: would move the
start date to January 2002
and place a $4,000 out-of-
pocket limit on beneficiary
liability in 2002 (indexed in
future years to drug
inflation).
Standard coverage in 2003:
After  $250 deductible, the
plan would pay 50% of costs
up to the next $2100 (i.e.,
$1,050 paid by plan, $1,050
paid by beneficiary).  The
plan would pay no costs for
spending between $2,350
and $7,050.  The plan would
pay 100% of costs when out-
of-pocket costs reached
$6,000 ($7,050 in total
spending).  Dollar amounts
would be increased annually
by annual percent increase in
per capita expenditures for
covered drugs.  Specific
requirements would apply if
an entity offered coverage of
non-drug benefits and these
non-drug benefits included
coverage of Medicare cost-
sharing charges; in this case
the plan would have to cover
at least what would be
covered under a basic
Medigap plan (Plan A). 
Program would pay 50% of
applicable limit: In
2002-2004, the program
would pay up to  $1,000 per
person per year (out of the
first $2,000 in total
spending). In 2005-2007, it
would pay up to $1,500 (out
of the first $3,000 in total
spending). In 2008, it would
pay up to $2,000 (out of the
first $4,000 in total
spending). In 2009, it would
pay up to $2,500 (out of the
first $5,000 in total
spending). Beginning in
2010, the limit would be
increased by the increase in
the CPI. 
In 2003: After $250
deductible, the plan would
pay 50% of the next $6,500
($6,750 total spending,
$3,500 total out-of-pocket),
25% of the next $2,000
($8,750 total spending,
$4,000 out-of-pocket). The
plan would pay 100% of
costs when out-of-pocket
costs reached $4,000 ($8,750
total spending). Beginning in
2005, the dollar amounts
would be increased by the
percentage increase in
program spending for drugs.
The benchmark packages
from which a state could
select would be Medicaid
coverage offered in the state,
coverage offered to state
employees, coverage offered




Plan (FEHBP) coverage 
provided under the standard
Blue Cross and Blue Shield
service benefit plan. If an
individual was covered under
the default program, the
benefit would be equivalent



















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)






No deductible.  Standard Coverage: $250
(2003).
No deductible. $250 (2003).  Under certain
circumstances, the entity
administering the benefit
could waive the deductible
for generic drugs. (In this
case any coinsurance paid












S.  2807, Medicare
Prescription Drug and





Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




For 2003:  After deductible,
beneficiaries would pay 50%
on the next $2,100 of costs.  
Beneficiaries would pay 50%
of  negotiated price up to the
coverage limit for a given
year.  Benefit managers
could propose a lower
percentage for certain classes
of drugs, provided that
aggregate costs would not be
increased. 
For 2003:  After deductible,
beneficiaries would pay 50%
on the next $2,100 of costs.
Beneficiaries would pay 50%
of negotiated price up to the
coverage limit for a given
year.  Private entities
administering the benefit
could propose a lower
percentage for certain classes
of drugs, provided that
aggregate costs would not be
increased. 
For 2003: After deductible,
beneficiaries would pay 50%
on the next $6,500 ($6,750
total, $3,500 total out-of-
pocket) and 25% of the next




benefit could reduce cost-
sharing. It could also require
higher cost-sharing for non-
formulary drugs, except
where such drugs were
determined to be medically
necessary.
A plan could not impose any
premium or cost-sharing on a
beneficiary whose family
income was below 100% of
the poverty line.  Any such
charges imposed on other
persons would be set on a
sliding scale based on
income. The annual
aggregate of such premiums
or cost-sharing for all
Medicare beneficiaries in a
family could not exceed 5%



















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)





premiums as part of
negotiations with  MBA.
Premiums could not vary




for 2003 is $35-$40.
Beneficiaries would pay a
premium equal to 50% of
program costs. (If a former
employer buys coverage for
former employees, it would
pay premiums equal to 2/3 of
the program costs.) 
Estimated monthly premium
would be $26 for 2003.
JUNE 24, 2000 REVISION:
specifies premium would be
$25 in 2002 and would not
be increased to reflect cost of
placing limit on out-of-
pocket expenses.
All plans would be required
to charge a uniform premium
for individuals enrolled in
the plan in the same service
area. The Commissioner
would pay to each eligible
entity the full amount of the
premium for each beneficiary
minus administrative costs
levied on the plan. 
Beneficiaries would pay the
premium amount (less any
discount) in the same manner
as Part B premiums are paid
(generally as a deduction
from an individual’s social
security check). All
beneficiaries would receive a
discount of at least 25%; this
discount would be included
as taxable income to the
beneficiary.
Beneficiaries would pay a
premium equal to 50% of
program costs. (Premiums
paid by former employers
would equal 2/3 of the
program cost.)
In general, beneficiaries
would pay a premium equal
to 50% of program costs; the
remaining 50% would be
paid by the federal
government. (Premiums paid
by former employers would
equal 2/3 of the program
cost.)  Higher income
beneficiaries would receive a
lower premium contribution
from the federal government. 
Individuals with adjusted
gross incomes between
$75,000 and $100,000 and
couples with adjusted gross
incomes between $150,000
and $200,000 would have the
government premium
contribution reduced from
50% to 25%, calculated on a
sliding scale basis. (These
income amounts would be
adjusted for inflation as
measured by the consumer
price index for years after
2003). All beneficiaries




Access to Negotiated Prices










Modernization Act of 2000
(Senators Breaux and
Frist)
S. 2541 Mecare Expansion
for Needed Drugs (MEND)




Act of 2000 (Senator
Graham et al.)




Plans would have to provide
access to negotiated prices
(including applicable
discounts) even when no
benefits are payable.
Prices would be negotiated




access to these prices even
after they hit the cap. 
Plans would have to provide
access to negotiated prices
(including applicable
discounts) even when no
benefits are payable
Prices would be negotiated
by private entities  with
manufacturers, wholesalers,
and pharmacies. 
The contracting entities bid
would include a proposal for
the estimated prices for
covered drugs and projected
annual increases in prices.
Entities contracts with retail
pharmacies would provide
that charges for drugs could



















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)








NEW AGENCY – Not
applicable.
NEW AGENCY –
Establishes a new executive
branch agency,  Competitive
Medicare Agency (CMA),





Board would be set up to
advise the Commissioner.
NEW AGENCY –  Not
applicable.
NEW AGENCY - Not




be established to advise the
Secretary on policies related
to administering the new
benefit.
NEW AGENCY –  Not
applicable.
FUNCTIONS –  The MBA
would: administer both the
new Part D (drugs) and Part
C (the M+C program); enter
into contracts with PDPs;
negotiate terms and
conditions of contracts with
PDPs,  establish process to
administer subsidy program;
make reinsurance payments
to PDPs or M+C plans; and
determine actuarial value of
coverage and annual percent
increases in standard
coverage levels.  The Office
of Beneficiary Assistance
(OBA) within the MBA




of information on appeal
rights.
FUNCTIONS – HHS would
designate at least 15 service
areas nationwide and enter
into a contract with one
entity to serve as the  benefit
manager for the area.  The
initial contract would be
awarded for 3-5 years and
could be renewed
noncompetitively. In
addition, the Secretary would
determine monthly premiums
and  conduct Part D 
enrollment.














of beneficiary eligibility and
enrollment with the
Commissioner of Social
Security; 2) negotiating the
terms and conditions of
contracts with entities and




FUNCTIONS – HHS would
designate at least 15 service
areas nationwide and enter
into a contract with one
private entity to administer
the benefit for the area.  The
initial contract would be
awarded for 2-5 years and
would be subject to review
after 2 years. In addition, the
Secretary would determine
monthly premiums and 
conduct Part D  enrollment.
FUNCTIONS: HHS would
establish at least 10 different
coverage areas nationwide. It
would award at least two
contracts per area to entities
to administer the benefit
unless only one entity met
the bidding requirements. 
Each contract would be







information on each entity
contracting to administer the
benefit in the area. The
Secretary would determine
the part D premium. The
Secretary would make
determinations (on the basis
of tax return information
FUNCTIONS - HHS would
review state plans and
amendments; these would be
considered approved unless
the Secretary notified the
state or group of states
within 45 days of either
disapproval or the need for
additional information. A
default program would be
established in a fiscal year
for beneficiaries residing in a
state which failed to submit a
plan to the Secretary by the
required date.  For purposes
of the default program,
HCFA would: 1) establish
procedures for making
eligibility determinations; 2)
establish a process for
accepting bids, awarding
contracts, and making
payments to PBMs or other
entities under such contracts;
CRS-13















Drugs (MEND) Act of 2000
(Senator Daschle et al.)
S. 2758 Medicare
Outpatient Drug (MOD)
Act of 2000 (Senator
Graham et al.)




benefits and quality; 4)
disseminating of appeals
rights information; and 5)
establishing a Medicare
beneficiary education
program.  The Commissioner
would also make reinsurance
payments to plans. The
Commissioner could
establish Medicare
Consumer Coalitions to help
provide information to
beneficiaries.
supplied by the Secretary of
the Treasury and any
information supplied by the
beneficiary) of modified
adjusted gross income (AGI)
for purposes of determining
those high-income persons
subject to higher premiums.
and 3) establish policies and
procedures for overseeing the
provision of assistance under
the contracts.  For FY 2001
only, HCFA would be
permitted to contract with
PBMs or other entities
without using competitive
bidding.  Each contract
would be for a uniform term
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The  Administrator would
provide reinsurance
payments for excess costs
incurred in providing
coverage. Percentage of costs
subject to reinsurance
payments would be increased
from 30% for costs over
$1,250 to 90% of costs
exceeding $1,550 but below
$2,300; reinsurance
payments also provided for
90% of costs exceeding
$6,000 out-of-pocket limit. 
The Administrator would
also be authorized to provide
financial incentives to secure
access to plans.
Payments would be made to
benefit managers under
terms of the contract. The
Secretary could provide
incentives for cost and
utilization  management
including: bonus and penalty
incentives to encourage
efficiency, incentives for
sharing of any benefit
savings achieved, and risk
sharing arrangements related
to benefit payments.  
The Commissioner would
pay to each entity the full
amount of the premium for
each beneficiary minus
administrative costs levied
on the plan. The
Commissioner would provide
for reinsurance payments
equal to 80% of costs
exceeding $7,050 (the point
at which beneficiary out-of-
pocket costs cease). 
Payments would be made to
private entities administering
the benefit under terms of
the contract. The Secretary
could provide incentives for
cost and utilization 
management including:
bonus and penalty incentives
to encourage efficiency,
incentives for sharing of any
benefit savings achieved, and
risk sharing arrangements





which entities would be only
subject to limited risk. The
procedures could include the
use of risk corridors tied to
performance measures that
were agreed to under the
contract as well as any other
incentives the Secretary
determined appropriate.
The Secretary would make
quarterly payments to each
state with an approved plan
from the state’s allotment. 
States would determine
payments to any benefit
administrator. Under the
default program, the contract
with the PBM or other entity
would specify the amount
and manner in which
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The PDP sponsors and M+C
organizations would offer
plans to beneficiaries.  They
would provide plan
information to beneficiaries;
assure access to pharmacies;
assure quality; have an
appeals process; and
maintain records and patient
confidentiality. PDP
sponsors would have to be
licensed by the state or meet
alternative requirements.
The benefit manager for an
area would: establish,
through negotiations, a




records comply with program
quality requirements; and
have in place education
activities.
Private entities and M+C
plans would offer plans to
beneficiaries. They would




confidentiality, and have in
place cost and utilization
management programs.
Entities would have to be
licensed by the state or meet
alternative requirements.
The private entity  for an
area would: establish,
through negotiations, a




records and comply with
program quality
requirements; and have in
place education activities.
Contracting entities and
M+C plans would offer plans






requirements, have in place
appeals procedures, and
maintain records and patient
confidentiality.
State programs would be
administered by the states. 
A state or group of states
would submit a written plan
to the Secretary of HHS
which  1) described how the
state, or group of states,
intended to use the funds;
and 2) included a description
of the budget for the plan
(updated periodically as
necessary) and details on the
planned use of funds, sources
of the non-federal share of
plan expenditures, and any
cost-sharing requirements.  A
state would be required to
submit a plan, which the
Secretary found met the
applicable requirements, by
September 1 prior to the start
of the fiscal year, except that
the submission for FY2001
would have to occur by
December 30, 2000.  
CRS-16
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If a M+C plan offered
prescription drug coverage, it
would have to be “qualified
coverage.” Beneficiaries
enrolled in plans offering
coverage would have to
obtain coverage through the
M+C.
Enrollees in managed care
plans would receive their
benefit through the M+C
organization.
If a M+C plan offered
prescription drug coverage, it
would have to be “qualified
coverage.” Beneficiaries
enrolled in plans offering
coverage would have to
obtain coverage through the
M+C.
Enrollees in managed care
plans would receive their
benefit through the M+C
organization.
Enrollees in managed care
plans would receive their
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Plans could use formularies
and other cost and utilization
controls, including incentives
to use generics.  An enrollee
would have the right to
appeal to obtain coverage for




on the formulary was not as
effective or had significant
adverse effects.
Benefit managers could use







would have appeal rights
when coverage was denied.  






higher cost-sharing for use of
brand name instead of
generic drugs or use of off-
formulary drugs), selective
contracting with providers of
drugs, and mail order
pharmacies. Entities would
be required to have a process
for beneficiaries to appeal
denials of coverage based on
application of the formulary.
Private entities administering
the benefit could use







would have appeal rights
when coverage was denied.
Contracting entities could




methods and generic drug
substitution.  Formularies
would have to comply with
standards established by the
Secretary in consultation
with the Medicare Pharmacy
and Therapeutics Advisory
Committee.  Entities would
be required to cover
nonformulary drugs when
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sharing would be nominal;
subsidy could not exceed
95% of maximum amount
that could be incurred for
standard coverage. ABOVE
135% AND BELOW 150%
OF POVERTY – Sliding
scale premium subsidy from
100% (at 135% of poverty)





would pay Part D drug
premiums and coinsurance
charges (up to the benefit
limit). ABOVE 135% AND
BELOW 150% OF
POVERTY – Medicaid
would pay, on a sliding
scale, based on income, a
portion of the premium. No
cost-sharing subsidy.  For
“Qualified Medicare drug
beneficiaries” (persons with
incomes between 100% and
150% of poverty and assets
below $4,000 for an
individual and $6,000 for a
couple) benefits would be
paid 100% by the federal
government for persons not





would have a discount on
their premium equal to 100%
of the value of standard drug
coverage provided under the
plan. Beneficiary cost-
sharing for such individuals
would be nominal.  ABOVE
135% AND BELOW 150%
OF POVERTY – There
would be a sliding scale
discount on their premiums
ranging from 100% of the
value of standard drug
coverage at 135% of poverty
to 25% of such value at





pay  Part D drug premiums
and coinsurance charges (up
to the benefit limit). 
ABOVE 135% AND
BELOW 150% OF
POVERTY –  Medicaid
would pay, on a sliding scale
based on income, a portion of




incomes between 100% and
150% of poverty and assets
below $4,000 for an
individual and $6,000 for a
couple) benefits would be
paid 100% by the federal
government for persons not









apply for those below 120%
of poverty; 100% federal
matching would apply for
those between 120/% and
135% of poverty. ABOVE
135% AND BELOW 150%
OF POVERTY –
Beneficiaries would pay a
reduced premium, calculated
on a sliding scale basis. The
federal matching rate would
be 100%.
The Secretary would make
quarterly payments to each
state with an approved plan
from the state’s allotment.
BENEFICIARIES AT OR
BELOW 135% OF
POVERTY - The federal
payment from the allotment
would be 100% of the costs





HIGH DRUG COSTS - The
federal payment would equal
an enhanced federal
matching rate,  defined as
the federal matching rate for
the state’s Medicaid program
plus 30% of the percentage
point difference between this
rate and 100%. In no case
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Part D would be the primary
payor with Medicaid paying
remaining costs for dual




and cost-sharing for dual
eligibles. States would make
eligibility determinations
with phase-in of increasing
matching rates for these
activities.  Medicaid drug
price rebates would not apply
for dual eligibles where a
PDP or M+C plan had
already negotiated discounts
under Part D.
States could choose to pay
Part D premiums and cost-
sharing for those persons
dually eligible for Medicare
and full Medicaid benefits
instead of providing drug
benefits through Medicaid. If
they elected this option,
States would have to cover
all dually eligible persons 
under Part D, buy all
prescriptions for such
individuals according to Part
D requirements, and cover
drugs in excess of the Part D
limits. For  persons below
100% of poverty, Medicaid
would have to pay Part D
premium and cost-sharing
charges.   For all persons
below 100% of poverty, the
current federal/state
matching rate would apply. 
(See also LOW-INCOME
SUBSIDIES, above). 
Medicaid drug price rebates
would not apply to
prescription drugs purchased
under Part D. 
The new Title XXII would
be the primary payer with
Medicaid paying remaining
costs for dual eligibles. 




for dual eligibles. States
would make eligibility
determinations with phase-in
of increasing matching rates
for these activities.  
States could choose to pay
Part D premiums and cost-
sharing for those persons
dually eligible for Medicare
and full Medicaid benefits
instead of providing drug
benefits through Medicaid. If
they elected this option,
states would have to cover to
all dually eligible persons 
under Part D, buy all
prescriptions for such
individuals according to Part
D requirements, and cover
drugs in excess of the Part D
limits. For  persons below
100% of poverty, Medicaid
would have to pay Part D
premium and cost-sharing
charges.   For all persons
below 100% of poverty, the
current federal/state
matching rate would apply. 
(See also LOW-INCOME
SUBSIDIES, above). 
Medicaid drug price rebates
would not apply to
prescription drugs purchased
under Part D.
Part D would be the primary
payor with Medicaid paying
remaining costs for dual
eligibles.  States would make
eligibility determinations for
persons below 150% of
poverty. Regular
federal/state matching would
apply for those below 120%
of poverty; 100% federal
matching would apply for
those between 120/% and
150% of poverty.
The new program would be
separate from Medicaid. 
Persons eligible for drug
benefits under Medicaid
would not be eligible for
benefits under Title XXII. 
The one exception is the case
of a state which had
established a drug program
for Medicare beneficiaries
under a Medicaid waiver. 
CRS-19
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could be issued after January
1, 2003. Beneficiaries
currently enrolled in
Medigap plans with drug
coverage could keep that
coverage. Beneficiaries
terminating enrollment in a
Medigap policy with a drug
benefit would be guaranteed
enrollment in a non-drug
policy if enrollment occurred
within 63 days of prior
coverage.
Medigap policies would be
revised to conform to the
revised program structure. 
No new Medigap
prescription drug policies
could be issued after January
1, 2003. Beneficiaries
currently enrolled in
Medigap plans with drug
coverage could keep that
coverage. Beneficiaries
terminating enrollment in a
Medigap policy with a drug
benefit would be guaranteed
enrollment in a non-drug
policy if enrollment occurred
within 63 days of prior
coverage. 
Not specified. Medigap plans offering drug
coverage would have to be
revised to complement, not
duplicate Part D. The revised
drug packages could not offer
coverage for either the Part
D deductible or for more
than 90% of the Part D
coinsurance.
A policyholder could request
suspension of benefits and
premiums payable under a
Medigap policy during the
period the policyholder was
covered under a state
program or the default
program. The policyholder
would automatically be
reinstated in the Medigap
plan if they notified the plan
within 90 days of the loss of
coverage under the state
program or the default
program.
Relationship to Group Health Plans
Qualified retiree plans would
be eligible for reinsurance
subsidies. The sponsor of the
plan would be required to
attest that coverage met
requirements for qualified
coverage.
Employers would receive a
partial subsidy if their retiree
health coverage for drugs
was at least as good as the
Part D benefit; the subsidy
would equal b of the
amount the government
would pay toward the
premium if the individual
were enrolled in Part D  The
Secretary would make these
premium subsidy payments
to the health plan sponsor
used by the employer. 
Qualified retiree plans would
be eligible for reinsurance
subsidies. The sponsor of the
plan would be required to
attest that coverage met
requirements for qualified
coverage. 
Employers would receive a
partial subsidy if their retiree
health coverage for drugs
was at least as good as the
Part D benefit; the subsidy
would equal to b of the
amount the government
would pay toward the
premium if the individual
were enrolled in Part D The
Secretary would make these
premium subsidy payments
to the health plan sponsor




receive a partial subsidy if
their retiree health coverage
for drugs was at least as good
as the Part D benefit; the
subsidy would equal to b of
the amount the government
would pay toward the
premium if the individual
were enrolled in Part D. 
No federal matching funds
would be available to the
extent a private insurer
would have been obligated to
provide assistance but for an
exclusion provision in its
insurance contract;  private
insurers covered under this
provision would include
group health plans, service
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A separate account — the
Medicare Prescription Drug
Account — would be
established within the Part B
trust fund.  Payments under
Part D would be kept
separate from all other Part
B funds.
A separate account — the
Prescription Drug Insurance
Account — would be set up
within the Part B trust fund.
Premiums would be credited
to the account and benefit
payments made from the
account.  
A separate account — the
Medicare Prescription Drug
Account — would be
established within the Part B
trust fund.  Payments under
the new Title XXII would be
kept separate from all other
Part B funds.  The annual
reporting requirements for
the Board of Trustees of the
Part A and Part B trust funds
would be expanded to
include a report on the two
trust funds as well as the
Medicare Prescription Drug
Account. The report would
include information on total
amounts obligated from the
general revenues of the
Treasury for benefits; a
historical overview of
spending; 10-year and 50-
year projections; and overall
spending from general
revenues in relation to gross
domestic product (GDP)
growth.
A separate account — the
Prescription Drug Insurance
Account —  would be set up
within the Part B trust fund.
Premiums would be credited
to the account and benefit
payments made from the
account.
Part D premiums would be
credited to the Part B trust
fund, and Part D costs would
be paid from the Part B trust
fund.  Part D costs would be
excluded from the
determination of the Part B
premium. The bill would
authorize the appropriation
of such sums as are
necessary, beginning in
FY2001, for the
administration of the Part D
program.
S. 3016 would appropriate
the following amounts for
purposes of making
allotments to the states: $1.2
billion in FY2001, $4.2
billion in FY2002, $9.0
billion in FY2003, and $3.0
billion in FY2004. The
amounts under S. 3017
would be: $1.3 billion in FY
2001; $4.6 billion in FY
2002; $9.7 billion in FY
2003; and $13.0 billion in
FY 2004. The Secretary
would allocate the amount
appropriated in a fiscal year
to the states with approved
plans.  The amount available
for allocation would be
reduced by any amounts
made available to the
territories (0.25% from the
total amount available).  The
amount allocated to each
state would bear the same
ratio to the total allotment
amount as the ratio of the
number of the state Medicare
beneficiaries below 150% of
poverty (175% under S.
3017) bore to the number of
such beneficiaries in all
states with plans.  A
minimum allotment available
to any state would be 0.5
percent of total allotments
CRS-21
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proportionately adjusted. If a
state did not submit a plan to
the Secretary by the required
date, 90% of the allotment
for the state would be made
available to the Secretary for
purposes of administering
the default program; the
other 10% would be
redistributed among states
with plans.
